BCAB

BioAtla is a pre-revenue clinical-stage oncology company that has quietly crossed from 'high-risk biotech' into 'balance-sheet distress.' FY2025 ended with just $7.12M cash (down 85.5% YoY) against a $48.2M annual operating cash burn — that is roughly a month or two of runway, not a year. Total assets collapsed 73.6% to $13.8M while liabilities rose 31.1% to $50.0M, leaving stockholders' equity at -$36.2M and an accumulated deficit of $545.6M. Current liabilities ($21.9M) are nearly triple current assets ($8.01M). The P/S of 886x is meaningless because there is no recurring product revenue; the only revenue in the dataset is a one-time $300K back in FY2021.

The filing narrative confirms this is a distressed situation, not a growth story. On March 2, 2026 the Board initiated a 'formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets' — the classic language of a company that cannot fund itself and is seeking a buyer, licensing deal, or orderly wind-down. Management explicitly lists 'our ability to continue as a going concern' and the outcome of a Nasdaq 'Delist Determination' review by the Listing Council among its forward-looking risks. It has already executed a 30% workforce cut (March 2025), halved its lease footprint (June 2025), a further reduction-in-force (March 2026), and is 're-evaluating the timing and scope' of its clinical programs — deferring both BA3182 Phase 1 enrollment and the planned BA3021 Phase 3 start. R&D spend was cut 30.9% to $43.6M, meaning the pipeline itself is being throttled to preserve cash.